Fundraising FoxNohla Therapeutics
Seattle, US · Founded 2015 · Delaware corporation · 4 known investors
Find your way into Nohla Therapeutics
Sign up to see every warm intro you have to Nohla Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nohla Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DS
Darren ScottiExecutive
BS
Benjamin Scot BergoExecutive
Board
LG
Lawrence GozlanBoard director
ID
Ian David BrownBoard director
Investors · 4
5AM VenturesreportedSan Francisco · $100K – $4M
How we know: press coverage · Not right? Tell us
AlexandriareportedPasadena
How we know: press coverage · Not right? Tell us
ARCH Venture PartnersreportedChicago · $50K – $250M
How we know: press coverage · Not right? Tell us
Premier PartnersreportedSeoul
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$79.4M disclosed across 3 rounds · 2015–2018
▶$45MraisedMay 2018 · 10 investors · BiotechnologyRule 506(b)
▶$45MraisedMay 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven GillisDirector
- Jim JohnsonExecutive Officer
- Lawrence GozlanDirector
- Michael SistenichDirector
- Brian DanielsDirector
- Gary ChristiansonExecutive Officer
- Colleen DelaneyExecutive Officer
- Kathleen FanningExecutive Officer, Director
- Offering amount
- $58.4M
- Amount sold
- $45M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$32.4MraisedNov 2017 · 13 investors · BiotechnologyRule 506(b)
▶$32.4MraisedNov 2017 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence GozlanDirector
- Kathleen FanningExecutive Officer, Director
- Michael SistenichDirector
- Steven GillisDirector
- Brian DanielsDirector
- Offering amount
- $41.5M
- Amount sold
- $32.4M
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$2MraisedDec 2015 · 9 investors · BiotechnologyRule 506(b)
▶$2MraisedDec 2015 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence GozlanDirector
- Ian David BrownDirector
- Darren ScottiExecutive Officer
- Benjamin Scot BergoExecutive Officer, Director, Promoter
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Nohla Therapeutics's investors?
- Nohla Therapeutics's investors include 5AM Ventures, Alexandria, ARCH Venture Partners, Premier Partners.
- How much funding has Nohla Therapeutics raised?
- Nohla Therapeutics has disclosed $79.4M raised across 3 rounds.
- Where is Nohla Therapeutics headquartered?
- Nohla Therapeutics is headquartered in Seattle, US.